InduPro Raises $77 Million Series B and Advances Lead Oncology Program IDP-001 Into Phase 1 Clinical Development
InduPro, Inc., a biotechnology company developing a new class of therapeutics based on the spatial organization of proteins on cell surfaces, has announced two significant milestones in the advancement of its oncology pipeline. The company has successfully closed a $77 million Series B financing and has dosed the first patient in the Phase 1 clinical study of IDP-001, its lead oncology program.
The financing will provide InduPro with capital to support the clinical development of IDP-001, generate early proof-of-concept data, and advance additional programs within the company’s preclinical pipeline. The Series B round was led by The Column Group and included participation from several existing investors, including Vida Ventures, MRL Ventures Fund, Emerson Collective, and Euclidean Capital. New investors joining the financing included Solasta Ventures, Sanofi, and Eli Lilly and Company.
The combined financing and clinical milestone mark an important stage in InduPro’s development as the company works to translate its proximity-guided drug discovery platform into potential therapies for patients with cancer and autoimmune diseases.
Advancing a New Approach to Precision Therapeutics
InduPro is building its therapeutic discovery strategy around the concept of biological proximity. Conventional drug discovery approaches often focus on identifying individual proteins or molecular targets that are present or overexpressed in diseased cells. InduPro’s technology takes a different approach by examining how proteins are spatially organized on the surface of cells.
The company has developed a proximity-guided platform designed to map the spatial relationships between membrane proteins and identify protein combinations that may create selective therapeutic opportunities.
This approach is particularly relevant to the development of bispecific medicines, which are designed to recognize two different targets simultaneously. By identifying protein pairs that are positioned close together on cancer cells but not in normal tissue, InduPro aims to develop therapies that can selectively exploit those disease-specific spatial relationships.
The company’s strategy could potentially open new avenues for precision medicine in tumor types where conventional target-based approaches have been less successful.
Prakash Raman, Ph.D., Chief Executive Officer of InduPro, said the company is pleased to have the support of a group of life sciences investors and strategic partners that recognize the potential of its proximity-guided platform. He emphasized that with IDP-001 now entering clinical development, the company’s immediate priority is disciplined execution of the Phase 1 program.
According to Raman, InduPro has progressed the program efficiently and has received strong early interest from principal investigators and clinical sites as enrollment expands.
$77 Million Series B Financing
The $77 million Series B financing provides InduPro with resources to advance IDP-001 through early clinical development while continuing to develop its broader pipeline.
The financing was led by The Column Group, a venture capital firm focused on life sciences investments. Existing investors Vida Ventures, MRL Ventures Fund, Emerson Collective, and Euclidean Capital also participated.
The round additionally attracted new strategic and financial investors, including Solasta Ventures, Sanofi, and Eli Lilly and Company. Participation from pharmaceutical companies and specialist biotechnology investors provides InduPro with not only financial support but also potential access to strategic expertise as its programs progress.
The capital is expected to fund several areas of activity, including the Phase 1 clinical evaluation of IDP-001, generation of preliminary proof-of-concept data, and advancement of additional preclinical programs based on the company’s proximity-guided discovery platform.
The successful financing also provides an indication of investor interest in alternative approaches to target discovery and precision oncology, particularly technologies capable of identifying therapeutic opportunities that may not be apparent through conventional genomic or protein-expression analyses.
IDP-001 Enters the Clinic
Alongside the financing announcement, InduPro reported that the first patient has been dosed in the Phase 1 clinical study of IDP-001.
The open-label, first-in-human trial, registered under NCT07602842, is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of IDP-001.
The study will evaluate IDP-001 as a monotherapy in adults with advanced or metastatic squamous or non-squamous non-small cell lung cancer (NSCLC) and other squamous solid tumors whose disease has progressed following standard-of-care treatment.
As an early-stage clinical trial, the study is primarily intended to characterize the safety and tolerability profile of the investigational therapy. Researchers will also assess how the drug behaves in the body through pharmacokinetic measurements and look for preliminary evidence of antitumor activity.
The first-patient dosing milestone represents a transition from laboratory and preclinical development into human clinical testing. Data generated during the trial will be important for determining whether the biological rationale underlying IDP-001 can translate into meaningful therapeutic activity in patients.
Addressing Unmet Needs in Squamous Cancers
InduPro is initially developing IDP-001 in cancer types where patients continue to face significant therapeutic challenges.
Advances in precision oncology have transformed treatment for several solid tumors by enabling physicians to match patients with therapies based on specific genetic alterations or molecular characteristics. However, these advances have not benefited all tumor types equally.
Squamous cancers, in particular, often have fewer actionable driver mutations than certain other malignancies. In addition, some cell-surface proteins that have become useful targets for approved antibody-drug conjugates are less commonly expressed or differently distributed in squamous tumors.
This creates a need for new approaches that can identify therapeutic vulnerabilities based on characteristics shared across cancer types rather than relying exclusively on specific genetic mutations.
InduPro believes that spatial organization of membrane proteins may represent one such opportunity. By examining how proteins are positioned relative to one another on cancer cells, the company aims to identify combinations of targets that can potentially support selective drug delivery.
Amanda J. Redig, M.D., Ph.D., Chief Medical Officer of InduPro, said the company developed IDP-001 to address the treatment gap in squamous cancers by using biological proximity as a therapeutic principle.
She explained that the targets selected for the bispecific ADC were chosen not only because of their shared biology across squamous tumors but also because of their spatial proximity on cancer cells. According to the company, this particular relationship is not found in normal tissue.
A Potential First-in-Class Bispecific ADC
IDP-001 is being developed as a potential first-in-class proximity-based bispecific antibody-drug conjugate (ADC) targeting EGFR and a novel Tumor-Associated Proximity Antigen (TAPA).
ADCs are designed to combine the targeting capabilities of antibodies with the cell-killing properties of therapeutic payloads. By directing a payload toward cells carrying selected molecular targets, ADCs can potentially deliver potent therapeutic agents more selectively than conventional systemic therapies.
IDP-001 takes this concept further by targeting two proteins simultaneously. The rationale is based on the spatial relationship between EGFR and the novel TAPA on cancer cells.
InduPro’s platform is designed to identify these types of protein neighborhoods and use them to guide the development of bispecific therapeutic molecules.
The company believes that exploiting proximity between two membrane proteins could potentially provide a greater degree of selectivity than targeting either protein individually. If successful, this strategy could help broaden the application of ADC technology to tumor types where conventional single-target approaches may have limitations.
Building a Broader Therapeutic Pipeline
While IDP-001 represents InduPro’s lead clinical program, the company is also using its platform to develop a broader preclinical pipeline focused on oncology and autoimmune diseases.
The underlying technology is intended to provide a systematic way to investigate membrane protein spatial relationships and identify previously overlooked combinations. This could potentially generate new therapeutic targets and expand the range of diseases that can be addressed using proximity-based drug design.
The company’s long-term strategy is therefore not limited to a single molecule or cancer type. Instead, InduPro is seeking to establish its proximity-guided platform as a discovery engine capable of generating multiple therapeutic candidates.
Sarah Hymowitz, Ph.D., Partner at The Column Group and Chair of InduPro’s Board of Directors, said the company’s induced-proximity platform has created an opportunity to investigate aspects of cell-surface biology that conventional target-discovery methods may overlook.
She highlighted the platform’s ability to map protein neighborhoods and use those findings to identify selective co-target pairs. The Column Group’s continued support, she said, reflects confidence in InduPro’s platform, scientific expertise, execution capabilities, and strategic relationships with pharmaceutical partners.
The next major focus for InduPro will be the clinical development of IDP-001. The Phase 1 trial will provide the company’s first opportunity to evaluate whether its proximity-guided approach can deliver the desired therapeutic effects in patients.
Safety and tolerability will be critical early objectives, followed by the evaluation of pharmacokinetics and preliminary antitumor activity. Data from the study could help guide future development decisions, including dose selection, patient populations, and potential expansion into additional tumor types.
For patients with advanced squamous cancers who have limited treatment options following standard therapies, new therapeutic strategies are urgently needed. InduPro’s approach is designed to address this need by looking beyond conventional genetic biomarkers and focusing on spatial relationships between proteins on cancer cells.
The $77 million Series B financing provides the company with the financial resources to advance this strategy, while the first patient dosing marks the beginning of clinical validation.
If the clinical program generates encouraging results, IDP-001 could establish proof of concept for InduPro’s proximity-guided approach and potentially support the advancement of additional programs based on the same platform.
Together, the financing and clinical milestone represent a significant step forward for InduPro. The company is now positioned to test its proximity-based therapeutic strategy in humans while continuing to expand its discovery pipeline. Through its focus on membrane protein spatial biology, InduPro aims to uncover new therapeutic opportunities in oncology and autoimmune disease and ultimately develop more selective medicines for patients with significant unmet medical needs.
About IDP-001
IDP-001 is a potential first-in-class, proximity-based bispecific ADC targeting EGFR and TAPA-E1, a novel Tumor-Associated Proximity Antigen. EGFR is a well-validated oncogenic target that is overexpressed across many solid tumors, but the challenge of balancing EGFR-directed toxicity while maintaining meaningful antitumor activity has thus far limited the impact of ADC therapeutics targeting EGFR. Dual targeting of EGFR and TAPA-E1 is designed to enhance tumor selectivity, target internalization, and antitumor efficacy without sacrificing tolerability, with the goal of expanding the therapeutic potential of targeting EGFR.
About InduPro’s Proximity-Guided Approach
InduPro therapeutically targets cell-surface proteins in a variety of disease contexts by leveraging inherent or induced protein proximity. Through precise mapping of protein neighborhoods using its proprietary, high-resolution proximity labeling technology, the Company is discovering novel co-target pairs that are highly selective for specific disease biology. Identifying and then validating these unique proximity-based pairings provides a novel approach for developing precision therapeutics to target the cellular signaling pathways that are critical for shaping disease. InduPro’s approach relies on a unique discovery engine to generate potential first-in-class and best-in-class novel therapeutic candidates across multiple indications and modalities.
About InduPro
InduPro, Inc. is a biotechnology company defining and harnessing inherent and induced proximity biology to unlock next-generation therapeutics in cancer and autoimmune diseases. The Company develops therapeutics against novel, tumor-selective proximity antigens and co-target pairs using bispecific antibodies, including antibody-drug conjugates (ADCs) and T-cell engagers (TCEs), fueling a robust pipeline of first- and best-in-class programs. To learn more, visit https://www.induprotx.com.